Share Price and Basic Stock Data
Last Updated: November 28, 2025, 7:47 am
| PEG Ratio | -6.34 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Camlin Fine Sciences Ltd operates in the specialty chemicals sector, focusing on various applications including food, pharmaceuticals, and agrochemicals. The company’s revenue has shown a fluctuating trend over the past few fiscal years. For the fiscal year ending March 2025, the total sales stood at ₹1,667 Cr, reflecting an increase from ₹1,454 Cr in the prior fiscal year. Quarterly sales figures also indicate volatility; for instance, sales peaked at ₹483 Cr in September 2022 but later declined to ₹377 Cr by March 2024. The trailing twelve months (TTM) revenue reached ₹1,752 Cr, suggesting a slight recovery following the previous dip. Such revenue fluctuations highlight the company’s reliance on market conditions and its ability to adapt to changing demand dynamics in the specialty chemicals market.
Profitability and Efficiency Metrics
Profitability metrics for Camlin Fine Sciences Ltd have been under pressure, as evidenced by its operating profit margin (OPM), which stood at a mere 4%. This is significantly lower than the typical sector range, reflecting challenges in managing costs relative to sales. The net profit for the fiscal year 2025 recorded a loss of ₹158 Cr, a stark contrast to the profit of ₹40 Cr reported in the previous year. The interest coverage ratio (ICR) was recorded at 2.23x, indicating the company’s ability to meet interest obligations but still pointing to financial strain. Efficiency ratios showed a cash conversion cycle of 143 days, which indicates a relatively slow turnover of inventory and receivables, thereby impacting liquidity. The return on equity (ROE) was reported at 15%, which is a positive indicator but could be improved given the company’s current financial challenges.
Balance Sheet Strength and Financial Ratios
Camlin Fine Sciences Ltd’s balance sheet reflects a total market capitalization of ₹3,076 Cr against total borrowings of ₹681 Cr. The debt-to-equity ratio stood at 0.71, suggesting a moderate level of leverage, which is manageable. The company reported reserves of ₹883 Cr, which provides a cushion against financial volatility. However, the low current ratio of 1.40 raises concerns regarding short-term liquidity. The price-to-book value ratio at 3.51x indicates that the stock might be overvalued compared to its book value, reflecting investor sentiment rather than underlying asset strength. Furthermore, the company has experienced a decline in net profit margins, which dropped to -9.51% in March 2025 from positive margins in previous years, indicating a need for strategic operational improvements to enhance profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Camlin Fine Sciences Ltd reveals a significant presence of promoters, holding 49.08% as of March 2025, which instills some confidence among investors regarding management’s commitment to the company. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 2.11% and 5.48% respectively, showing limited institutional interest, which can affect stock liquidity. The public shareholding stood at 43.33%, with a total of 57,661 shareholders. The gradual increase in promoter holding from 17.64% in December 2022 to the current level suggests a positive outlook from the management on future performance. However, the declining participation of FIIs, from 10.94% in December 2022 to 2.11% in March 2025, raises questions about broader market confidence in the company’s prospects.
Outlook, Risks, and Final Insight
Looking ahead, Camlin Fine Sciences Ltd faces several risks, including fluctuating raw material prices, which could further compress margins. The significant decline in net profits over the past fiscal periods raises concerns about the company’s operational sustainability. However, strengths such as a strong promoter backing and a diversified product portfolio provide a foundation for potential recovery. The company must focus on improving its operational efficiency to regain profitability and investor confidence. If it successfully navigates these challenges, there could be opportunities for growth, particularly in expanding its market presence in the specialty chemicals sector. Conversely, failure to address operational inefficiencies could lead to further financial distress, affecting its long-term viability in the market.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Camlin Fine Sciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 422 Cr. | 45.9 | 86.7/42.6 | 26.2 | 20.5 | 0.88 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 34.9 Cr. | 71.0 | 103/56.0 | 16.7 | 89.6 | 1.41 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 47.6 Cr. | 699 | 988/600 | 21.9 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,664 Cr. | 80.8 | 111/78.0 | 24.2 | 22.0 | 0.61 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 646 Cr. | 259 | 453/241 | 23.2 | 93.8 | 0.96 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,826.36 Cr | 735.46 | 63.36 | 183.02 | 0.43% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 384 | 483 | 388 | 427 | 420 | 406 | 386 | 377 | 381 | 423 | 431 | 437 | 424 |
| Expenses | 337 | 428 | 338 | 383 | 381 | 381 | 363 | 345 | 352 | 380 | 375 | 378 | 405 |
| Operating Profit | 47 | 55 | 50 | 44 | 39 | 25 | 23 | 31 | 29 | 43 | 56 | 59 | 19 |
| OPM % | 12% | 11% | 13% | 10% | 9% | 6% | 6% | 8% | 8% | 10% | 13% | 14% | 4% |
| Other Income | 1 | 3 | 10 | -8 | 6 | 2 | 2 | -96 | -15 | -138 | -8 | -17 | 3 |
| Interest | 19 | 18 | 12 | 10 | 10 | 20 | 14 | 16 | 23 | 26 | 34 | 16 | 16 |
| Depreciation | 14 | 14 | 16 | 18 | 19 | 19 | 21 | 13 | 15 | 21 | 14 | 18 | 17 |
| Profit before tax | 15 | 26 | 32 | 8 | 16 | -12 | -10 | -94 | -23 | -142 | -0 | 8 | -11 |
| Tax % | 75% | 61% | 28% | 59% | 25% | 72% | 47% | -13% | 48% | -18% | 2,164% | 99% | -0% |
| Net Profit | 4 | 10 | 23 | 3 | 12 | -21 | -14 | -82 | -35 | -116 | -7 | 0 | -11 |
| EPS in Rs | 0.33 | 0.74 | 1.36 | 0.52 | 0.83 | -1.03 | -0.63 | -4.11 | -1.81 | -5.33 | -0.22 | -0.04 | -0.53 |
Last Updated: August 20, 2025, 12:30 pm
Below is a detailed analysis of the quarterly data for Camlin Fine Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 424.00 Cr.. The value appears to be declining and may need further review. It has decreased from 437.00 Cr. (Mar 2025) to 424.00 Cr., marking a decrease of 13.00 Cr..
- For Expenses, as of Jun 2025, the value is 405.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 378.00 Cr. (Mar 2025) to 405.00 Cr., marking an increase of 27.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 59.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 40.00 Cr..
- For OPM %, as of Jun 2025, the value is 4.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to 4.00%, marking a decrease of 10.00%.
- For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from -17.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 20.00 Cr..
- For Interest, as of Jun 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Depreciation, as of Jun 2025, the value is 17.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 18.00 Cr. (Mar 2025) to 17.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Mar 2025) to -11.00 Cr., marking a decrease of 19.00 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 99.00% (Mar 2025) to 0.00%, marking a decrease of 99.00%.
- For Net Profit, as of Jun 2025, the value is -11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.00 Cr. (Mar 2025) to -11.00 Cr., marking a decrease of 11.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.53. The value appears to be declining and may need further review. It has decreased from -0.04 (Mar 2025) to -0.53, marking a decrease of 0.49.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:36 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 509 | 558 | 489 | 534 | 721 | 892 | 1,049 | 1,187 | 1,412 | 1,682 | 1,454 | 1,667 | 1,752 |
| Expenses | 446 | 474 | 397 | 502 | 705 | 819 | 914 | 1,000 | 1,254 | 1,468 | 1,284 | 1,447 | 1,584 |
| Operating Profit | 63 | 84 | 92 | 32 | 16 | 73 | 135 | 187 | 158 | 213 | 170 | 220 | 167 |
| OPM % | 12% | 15% | 19% | 6% | 2% | 8% | 13% | 16% | 11% | 13% | 12% | 13% | 10% |
| Other Income | 9 | 9 | -1 | 14 | 12 | 14 | 3 | 5 | 33 | -4 | -142 | -203 | -26 |
| Interest | 25 | 24 | 24 | 31 | 32 | 41 | 48 | 42 | 41 | 66 | 70 | 111 | 85 |
| Depreciation | 12 | 16 | 17 | 22 | 27 | 29 | 33 | 44 | 56 | 63 | 56 | 64 | 69 |
| Profit before tax | 35 | 53 | 50 | -6 | -31 | 17 | 58 | 105 | 94 | 80 | -99 | -158 | -12 |
| Tax % | 18% | -4% | 28% | -26% | -22% | 82% | 49% | 38% | 36% | 50% | 6% | 0% | |
| Net Profit | 29 | 55 | 36 | -4 | -24 | 3 | 30 | 65 | 60 | 40 | -105 | -158 | -33 |
| EPS in Rs | 2.71 | 5.11 | 3.30 | -0.96 | -2.18 | 0.04 | 2.23 | 3.56 | 3.45 | 2.96 | -4.94 | -7.40 | -1.55 |
| Dividend Payout % | 12% | 8% | 12% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 89.66% | -34.55% | -111.11% | -500.00% | 112.50% | 900.00% | 116.67% | -7.69% | -33.33% | -362.50% | -50.48% |
| Change in YoY Net Profit Growth (%) | 0.00% | -124.20% | -76.57% | -388.89% | 612.50% | 787.50% | -783.33% | -124.36% | -25.64% | -329.17% | 312.02% |
Camlin Fine Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 223% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 20% |
| 3 Years: | 19% |
| 1 Year: | 103% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -2% |
| 3 Years: | -7% |
| Last Year: | -15% |
Last Updated: September 5, 2025, 1:30 am
Balance Sheet
Last Updated: July 25, 2025, 3:27 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 10 | 10 | 10 | 12 | 12 | 12 | 13 | 16 | 16 | 17 | 19 |
| Reserves | 84 | 125 | 167 | 202 | 359 | 359 | 391 | 631 | 732 | 804 | 848 | 883 |
| Borrowings | 150 | 160 | 180 | 331 | 373 | 461 | 539 | 550 | 646 | 801 | 683 | 681 |
| Other Liabilities | 126 | 131 | 123 | 126 | 273 | 255 | 290 | 282 | 396 | 425 | 424 | 454 |
| Total Liabilities | 369 | 426 | 479 | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,037 |
| Fixed Assets | 83 | 106 | 140 | 201 | 278 | 272 | 306 | 584 | 601 | 858 | 816 | 704 |
| CWIP | 22 | 3 | 25 | 8 | 14 | 59 | 179 | 24 | 215 | 43 | 46 | 10 |
| Investments | 1 | 1 | 1 | 19 | 115 | 11 | 7 | 7 | 7 | 8 | 8 | 61 |
| Other Assets | 262 | 316 | 313 | 442 | 609 | 745 | 740 | 861 | 966 | 1,136 | 1,102 | 1,262 |
| Total Assets | 369 | 426 | 479 | 669 | 1,016 | 1,087 | 1,232 | 1,475 | 1,790 | 2,045 | 1,972 | 2,037 |
Below is a detailed analysis of the balance sheet data for Camlin Fine Sciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 17.00 Cr. (Mar 2024) to 19.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Mar 2025, the value is 883.00 Cr.. The value appears strong and on an upward trend. It has increased from 848.00 Cr. (Mar 2024) to 883.00 Cr., marking an increase of 35.00 Cr..
- For Borrowings, as of Mar 2025, the value is 681.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 683.00 Cr. (Mar 2024) to 681.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 454.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 424.00 Cr. (Mar 2024) to 454.00 Cr., marking an increase of 30.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,037.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,972.00 Cr. (Mar 2024) to 2,037.00 Cr., marking an increase of 65.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 704.00 Cr.. The value appears to be declining and may need further review. It has decreased from 816.00 Cr. (Mar 2024) to 704.00 Cr., marking a decrease of 112.00 Cr..
- For CWIP, as of Mar 2025, the value is 10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 46.00 Cr. (Mar 2024) to 10.00 Cr., marking a decrease of 36.00 Cr..
- For Investments, as of Mar 2025, the value is 61.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2024) to 61.00 Cr., marking an increase of 53.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,262.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,102.00 Cr. (Mar 2024) to 1,262.00 Cr., marking an increase of 160.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,037.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,972.00 Cr. (Mar 2024) to 2,037.00 Cr., marking an increase of 65.00 Cr..
Notably, the Reserves (883.00 Cr.) exceed the Borrowings (681.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -87.00 | -76.00 | -88.00 | -299.00 | -357.00 | -388.00 | -404.00 | -363.00 | -488.00 | -588.00 | -513.00 | -461.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73 | 74 | 56 | 99 | 104 | 86 | 88 | 83 | 77 | 66 | 72 | 72 |
| Inventory Days | 145 | 184 | 311 | 277 | 207 | 219 | 204 | 200 | 178 | 255 | 256 | 233 |
| Days Payable | 132 | 144 | 171 | 110 | 154 | 127 | 119 | 99 | 112 | 129 | 154 | 162 |
| Cash Conversion Cycle | 85 | 114 | 196 | 266 | 157 | 178 | 173 | 184 | 143 | 192 | 174 | 143 |
| Working Capital Days | -4 | 12 | 1 | -6 | 19 | 43 | 22 | 55 | 40 | 42 | 51 | 35 |
| ROCE % | 28% | 28% | 24% | 5% | 0% | 7% | 11% | 13% | 10% | 10% | 8% | 11% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Smallcap Fund | 4,283,136 | 1.16 | 70.22 | 4,283,136 | 2025-04-22 17:25:39 | 0% |
| HSBC Small Cap Equity Fund - OLD | 400,000 | 2.09 | 6.28 | 400,000 | 2025-04-22 17:25:39 | 0% |
| ICICI Prudential Dividend Yield Equity Fund | 224,082 | 0.15 | 3.67 | 224,082 | 2025-04-22 17:25:39 | 0% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 82,017 | 0.35 | 1.34 | 82,017 | 2025-04-22 17:25:39 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -8.03 | -5.58 | 3.45 | 4.65 | 4.13 |
| Diluted EPS (Rs.) | -7.95 | -5.50 | 3.41 | 4.56 | 3.68 |
| Cash EPS (Rs.) | -5.04 | -1.57 | 6.51 | 7.42 | 8.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 47.81 | 48.29 | 48.18 | 43.26 | 47.81 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 47.81 | 50.97 | 52.25 | 48.52 | 55.67 |
| Revenue From Operations / Share (Rs.) | 88.68 | 96.32 | 107.04 | 89.95 | 93.11 |
| PBDIT / Share (Rs.) | 11.84 | 5.34 | 13.44 | 11.84 | 14.66 |
| PBIT / Share (Rs.) | 8.45 | 0.64 | 9.46 | 8.27 | 11.19 |
| PBT / Share (Rs.) | 2.61 | -5.93 | 5.12 | 5.99 | 8.24 |
| Net Profit / Share (Rs.) | -8.44 | -6.26 | 2.53 | 3.85 | 5.13 |
| NP After MI And SOA / Share (Rs.) | -7.40 | -5.54 | 3.32 | 3.87 | 4.00 |
| PBDIT Margin (%) | 13.35 | 5.54 | 12.55 | 13.16 | 15.74 |
| PBIT Margin (%) | 9.52 | 0.67 | 8.83 | 9.19 | 12.01 |
| PBT Margin (%) | 2.94 | -6.15 | 4.77 | 6.66 | 8.85 |
| Net Profit Margin (%) | -9.51 | -6.50 | 2.36 | 4.28 | 5.50 |
| NP After MI And SOA Margin (%) | -8.34 | -5.75 | 3.09 | 4.29 | 4.29 |
| Return on Networth / Equity (%) | -15.47 | -11.35 | 6.92 | 9.16 | 9.43 |
| Return on Capital Employeed (%) | 13.47 | 0.89 | 11.72 | 10.77 | 14.20 |
| Return On Assets (%) | -6.87 | -4.75 | 2.52 | 3.37 | 3.43 |
| Long Term Debt / Equity (X) | 0.29 | 0.40 | 0.54 | 0.58 | 0.50 |
| Total Debt / Equity (X) | 0.71 | 0.80 | 1.04 | 0.94 | 0.99 |
| Asset Turnover Ratio (%) | 0.83 | 0.80 | 0.46 | 0.48 | 0.52 |
| Current Ratio (X) | 1.40 | 1.37 | 1.37 | 1.50 | 1.66 |
| Quick Ratio (X) | 0.77 | 0.66 | 0.65 | 0.87 | 0.99 |
| Inventory Turnover Ratio (X) | 3.21 | 1.38 | 1.29 | 1.65 | 1.79 |
| Interest Coverage Ratio (X) | 2.23 | 1.48 | 3.61 | 5.20 | 4.98 |
| Interest Coverage Ratio (Post Tax) (X) | 1.59 | 0.08 | 1.85 | 2.69 | 2.74 |
| Enterprise Value (Cr.) | 3620.14 | 2050.95 | 2685.65 | 2687.50 | 2251.73 |
| EV / Net Operating Revenue (X) | 2.17 | 1.27 | 1.60 | 1.90 | 1.90 |
| EV / EBITDA (X) | 16.27 | 22.92 | 12.72 | 14.46 | 12.05 |
| MarketCap / Net Operating Revenue (X) | 1.89 | 0.92 | 1.19 | 1.55 | 1.50 |
| Price / BV (X) | 3.51 | 1.83 | 2.66 | 3.31 | 3.30 |
| Price / Net Operating Revenue (X) | 1.89 | 0.92 | 1.19 | 1.55 | 1.50 |
| EarningsYield | -0.04 | -0.06 | 0.02 | 0.02 | 0.02 |
After reviewing the key financial ratios for Camlin Fine Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -8.03. This value is below the healthy minimum of 5. It has decreased from -5.58 (Mar 24) to -8.03, marking a decrease of 2.45.
- For Diluted EPS (Rs.), as of Mar 25, the value is -7.95. This value is below the healthy minimum of 5. It has decreased from -5.50 (Mar 24) to -7.95, marking a decrease of 2.45.
- For Cash EPS (Rs.), as of Mar 25, the value is -5.04. This value is below the healthy minimum of 3. It has decreased from -1.57 (Mar 24) to -5.04, marking a decrease of 3.47.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 47.81. It has decreased from 48.29 (Mar 24) to 47.81, marking a decrease of 0.48.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 47.81. It has decreased from 50.97 (Mar 24) to 47.81, marking a decrease of 3.16.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 88.68. It has decreased from 96.32 (Mar 24) to 88.68, marking a decrease of 7.64.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.84. This value is within the healthy range. It has increased from 5.34 (Mar 24) to 11.84, marking an increase of 6.50.
- For PBIT / Share (Rs.), as of Mar 25, the value is 8.45. This value is within the healthy range. It has increased from 0.64 (Mar 24) to 8.45, marking an increase of 7.81.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from -5.93 (Mar 24) to 2.61, marking an increase of 8.54.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -8.44. This value is below the healthy minimum of 2. It has decreased from -6.26 (Mar 24) to -8.44, marking a decrease of 2.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -7.40. This value is below the healthy minimum of 2. It has decreased from -5.54 (Mar 24) to -7.40, marking a decrease of 1.86.
- For PBDIT Margin (%), as of Mar 25, the value is 13.35. This value is within the healthy range. It has increased from 5.54 (Mar 24) to 13.35, marking an increase of 7.81.
- For PBIT Margin (%), as of Mar 25, the value is 9.52. This value is below the healthy minimum of 10. It has increased from 0.67 (Mar 24) to 9.52, marking an increase of 8.85.
- For PBT Margin (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 10. It has increased from -6.15 (Mar 24) to 2.94, marking an increase of 9.09.
- For Net Profit Margin (%), as of Mar 25, the value is -9.51. This value is below the healthy minimum of 5. It has decreased from -6.50 (Mar 24) to -9.51, marking a decrease of 3.01.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -8.34. This value is below the healthy minimum of 8. It has decreased from -5.75 (Mar 24) to -8.34, marking a decrease of 2.59.
- For Return on Networth / Equity (%), as of Mar 25, the value is -15.47. This value is below the healthy minimum of 15. It has decreased from -11.35 (Mar 24) to -15.47, marking a decrease of 4.12.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.47. This value is within the healthy range. It has increased from 0.89 (Mar 24) to 13.47, marking an increase of 12.58.
- For Return On Assets (%), as of Mar 25, the value is -6.87. This value is below the healthy minimum of 5. It has decreased from -4.75 (Mar 24) to -6.87, marking a decrease of 2.12.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has decreased from 0.40 (Mar 24) to 0.29, marking a decrease of 0.11.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.71. This value is within the healthy range. It has decreased from 0.80 (Mar 24) to 0.71, marking a decrease of 0.09.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.83. It has increased from 0.80 (Mar 24) to 0.83, marking an increase of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 1.5. It has increased from 1.37 (Mar 24) to 1.40, marking an increase of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.77, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.21. This value is below the healthy minimum of 4. It has increased from 1.38 (Mar 24) to 3.21, marking an increase of 1.83.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.23. This value is below the healthy minimum of 3. It has increased from 1.48 (Mar 24) to 2.23, marking an increase of 0.75.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.59. This value is below the healthy minimum of 3. It has increased from 0.08 (Mar 24) to 1.59, marking an increase of 1.51.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,620.14. It has increased from 2,050.95 (Mar 24) to 3,620.14, marking an increase of 1,569.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.17. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 2.17, marking an increase of 0.90.
- For EV / EBITDA (X), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 15. It has decreased from 22.92 (Mar 24) to 16.27, marking a decrease of 6.65.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 1.89, marking an increase of 0.97.
- For Price / BV (X), as of Mar 25, the value is 3.51. This value exceeds the healthy maximum of 3. It has increased from 1.83 (Mar 24) to 3.51, marking an increase of 1.68.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 1.89, marking an increase of 0.97.
- For EarningsYield, as of Mar 25, the value is -0.04. This value is below the healthy minimum of 5. It has increased from -0.06 (Mar 24) to -0.04, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Camlin Fine Sciences Ltd:
- Net Profit Margin: -9.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.47% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -15.47% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.59
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 191 (Industry average Stock P/E: 63.36)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.71
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -9.51%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Floor 2 to 5, In GS Point, Mumbai Maharashtra 400098 | secretarial@camlinfs.com https://www.camlinfs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ashish Dandekar | Chairman & Managing Director |
| Mr. Nirmal Momaya | Managing Director |
| Mr. Arjun Dukane | Executive Director -Technical |
| Mr. Joseph Conrad D'souza | Independent Director |
| Ms. Anagha Dandekar | Non Exe.Non Ind.Director |
| Mr. Harsha Raghavan | Non Exe.Non Ind.Director |
| Mr. Jens Van Nieuwenborgh | Non Exe.Non Ind.Director |
| Mr. Mahabaleshwar Palekar | Independent Director |
| Mr. Pradip Kanakia | Independent Director |
| Mr. Amol Shah | Independent Director |
| Ms. Radhika Dudhat | Independent Director |
| Mr. Abeezar Faizullabhoy | Independent Director |
FAQ
What is the intrinsic value of Camlin Fine Sciences Ltd?
Camlin Fine Sciences Ltd's intrinsic value (as of 29 November 2025) is 1105.80 which is 574.27% higher the current market price of 164.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 3,076 Cr. market cap, FY2025-2026 high/low of 335/110, reserves of ₹883 Cr, and liabilities of 2,037 Cr.
What is the Market Cap of Camlin Fine Sciences Ltd?
The Market Cap of Camlin Fine Sciences Ltd is 3,076 Cr..
What is the current Stock Price of Camlin Fine Sciences Ltd as on 29 November 2025?
The current stock price of Camlin Fine Sciences Ltd as on 29 November 2025 is 164.
What is the High / Low of Camlin Fine Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Camlin Fine Sciences Ltd stocks is 335/110.
What is the Stock P/E of Camlin Fine Sciences Ltd?
The Stock P/E of Camlin Fine Sciences Ltd is 191.
What is the Book Value of Camlin Fine Sciences Ltd?
The Book Value of Camlin Fine Sciences Ltd is 47.3.
What is the Dividend Yield of Camlin Fine Sciences Ltd?
The Dividend Yield of Camlin Fine Sciences Ltd is 0.00 %.
What is the ROCE of Camlin Fine Sciences Ltd?
The ROCE of Camlin Fine Sciences Ltd is 11.0 %.
What is the ROE of Camlin Fine Sciences Ltd?
The ROE of Camlin Fine Sciences Ltd is 15.0 %.
What is the Face Value of Camlin Fine Sciences Ltd?
The Face Value of Camlin Fine Sciences Ltd is 1.00.